Companies Dominating the Vaccine Adjuvants Landscape
- Pfizer Inc.
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- GSK plc
- SK Bioscience
- Sanofi
- Abbott
- Phibro Animal Health Corporation
- Astrazeneca
- Novavax, Inc.
- Agenus Inc.
- Astellas Pharma Inc.
Browse key industry insights with market data tables & charts from the report:
Frequently Asked Questions (FAQ)
Currently in 2025, the industry revenue of vaccine adjuvants is estimated at USD 2.28 billion.
The global vaccine adjuvants market is anticipated to grow from USD 2.2 billion in 2024 to USD 4.15 billion by 2037, witnessing a CAGR of around 5% throughout the forecast timeline, between 2025 and 2037.
North America industry is anticipated to account for largest revenue share of 35% by 2037, due to large population of elderly individuals and the increasing prevalence of chronic diseases, such as cancer, diabetes, and heart disease in the region.
The major players in the market include Pfizer Inc., GSK plc, SK Bioscience, Sanofi, Abbott, Phibro Animal Health Corporation, Astrazeneca, Novavax, Inc., Agenus Inc., Astellas Pharma Inc.
